C.M. Bidwell & Associates’s Supernus Pharmaceuticals SUPN Stock Holding History

C.M. Bidwell & Associates’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-61	Closed	-$1.68K	–	570
2023 Q3	$1.68K	Sell	61 -3,186	-98%	-$97K	﹤0.01%	487
2023 Q2	$97.6K	Sell	3,247 -935	-22%	-$32.7K	0.07%	244
2023 Q1	$152K	Buy	+4,182	New	+$161K	0.11%	158
2022 Q2	–	Sell	-2,922	Closed	-$94K	–	554
2022 Q1	$94K	Buy	2,922 +1,445	+98%	+$44.3K	0.06%	245
2021 Q4	$43K	Buy	+1,477	New	+$44.8K	0.03%	314
2021 Q2	–	Sell	-7,725	Closed	-$202K	–	618
2021 Q1	$202K	Buy	7,725 +7,625	+7,625%	+$213K	0.15%	132
2020 Q4	$3K	Buy	+100	New	+$2.15K	﹤0.01%	450
2020 Q3	–	Sell	-2,740	Closed	-$65K	–	510
2020 Q2	$65K	Buy	+2,740	New	+$60.5K	0.06%	236
2018 Q3	–	Sell	-970	Closed	-$58K	–	452
2018 Q2	$58K	Buy	+970	New	+$50.3K	0.05%	237

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

C.M. Bidwell & Associates's SUPN Position: Q4 2023 in Review

C.M. Bidwell & Associates sold out of Supernus Pharmaceuticals (SUPN) in Q4 2023, closing a stake of 61 shares — an estimated $1.68K sold.

C.M. Bidwell & Associates first reported a position in SUPN in Q2 2018 and held it in 9 quarters. The position peaked at $202K in Q1 2021. 246 funds tracked by Wall St. Rank hold SUPN as of Q4 2023.

C.M. Bidwell & Associates reported no remaining Supernus Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
C.M. Bidwell & Associates sold 61 Supernus Pharmaceuticals shares in Q4 2023, an estimated $1.68K.
C.M. Bidwell & Associates first reported a position in Supernus Pharmaceuticals in Q2 2018 and held it in 9 quarters.
C.M. Bidwell & Associates's Supernus Pharmaceuticals position peaked at $202K in Q1 2021.
246 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2023.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2023, filed 14 Feb 2024.